Lobbying Information
Subject Matters
- Economic Development
- Health
- Intellectual Property
- Research and Development
- Science and Technology
Subject Matter Details
Grant, Contribution or Other Financial Benefit
- Innovation agenda for the life sciences sector and implementation of superclusters, Strategic Innovation Fund
Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
- NAFTA negotiations and their impact on the life sciences industry
Legislative Proposal, Bill or Resolution, Regulation
- Canada European Trade Agreement Implementation (formerly Bill-C30), with respect to patent term restoration via Certificates of Supplementary Protection (CSP) and changes to Canada’s linkage regime for the pharmaceutical industry
- Patented Medicines Price Review Board Reform, with regard to the change of mandate (affordability vs. excessive pricing) the basket of countries, R&D calculation, the unintended consequences of these changes on the industry and provincial investments
Policies or Program
- Advocate for the implementation of a diabetes and obesity strategy at a federal level, to be cascaded down at a provincial level, to ensure better prevention, diagnosis and treatment of people with metabolic diseases (obesity, pre-diabetes, diabetes)
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
Government Institutions
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
NAFTA Secretariat
-
National Research Council (NRC)
-
Office of the Commissioner of Lobbying (OCL)
-
Patented Medicine Prices Review Board (PMPRB)
-
Senate of Canada
Government institutions added through a monthly communication report
- Canadian Institutes of Health Research (CIHR)
In-house Organization Details
Description of the organization's activities
Novo Nordisk Canada Inc. is a global leader in the development of therapies for diabetes, metabolic diseases and blood disorders. Novo Nordisk’s innovations in diabetes cover both the treatment as well as devices, and we are working hard to find a cure for diabetes and, short of that, to completely reduce diabetes as an obstacle to a healthy and productive life.
Responsible officer name and position during the period of this registration
Brian Hilberdink,
President
Organization's membership or classes of membership
Innovative Medicines Canada
BIOTECanada
Life Sciences Ontario
Government funding
No government funding was received during the last completed financial year.
In-house Organization Contact Information
Address:
2680 Skymark Avenue
Mississauga, ON L4W 5L6
Canada
Telephone number:
905-691-2208
Lobbyists Details
Employees who lobby for the organization
- Anne-Sophie Viard,
Federal Affairs manager |
No public offices held